摘要
目的 探讨舒芬太尼对胫骨骨折大鼠骨折术后骨愈合的影响。方法 选取48只雄性SD大鼠,麻醉下建立胫骨骨折模型,随机分为实验组(枸橼酸舒芬太尼注射液,10μg·kg^(-1)·12 h^(-1))和对照组(0.9%氯化钠溶液),在第1、2、4周时分别处死8只大鼠,X线片观察,HE染色观察组织学特征,测定血清碱性磷酸酶及转化生长因子β1水平,采用免疫组化法检测骨折处骨组织中骨形态发生蛋白2表达水平。结果 X线片观察到在1周、2周、4周时,实验组骨折愈合程度均低于对照组(P<0.05);HE染色结果显示在1周、2周、4周时,实验组骨折愈合程度均低于对照组;实验组和对照组血清碱性磷酸酶含量1周时开始上升,2周时含量最高,4周时逐渐降低,且在术后1周、2周、4周时,实验组大鼠的血清碱性磷酸酶含量均低于对照组(P<0.05)。2组血清转化生长因子β1含量在术后1周、2周、4周不断增高,且实验组大鼠的血清转化生长因子β1含量均低于对照组(P<0.05)。术后1周、2周、4周时,实验组大鼠的骨折部位的骨组织中骨形态发生蛋白2表达水平均低于对照组(P<0.05)。结论 舒芬太尼会抑制胫骨骨折大鼠的骨折愈合。
Objective To explore the effect of sufentanil(SF) on postoperative bone healing(BH) in rats with tibial fracture(TF).Methods The TF model was established in 48 healthy male SD rats under anesthesia,and the rats were randomly assigned to the experimental group(sufentanil citrate injection,10μg·kg^(-1)·12h^(-1)) and the control group(0.9% sodium chloride solution).Eight rats were sacrificed in weeks 1,2,4.The X-ray was performed for image observation;the histologic characteristics was observed using the HE staining.The serum alkaline phosphatase(ALP) and transforming growth factor beta 1(TGF-β1) were detected;the expression of bone morphogenic protein-2(BMP-2) in bone tissue at fracture was detected by immunohistochemistry.Results Both X-ray and HE staining showed that the BH rates on weeks 1,2 and 4 in the experimental group were lower than those in the control group(P<0.05).The serum ALP level in the two group increased on week 1,peaked on week 2,and decreased on week 4;the serum ALP level on weeks 1,2 and 4 in the experimental group was decreased as compared to the control group(P<0.05).The TGF-β1 level on weeks 1,2 and 4 in groups was continuously increased,which in the experimental group was decreased as compared to the control group(P<0.05).The expression of BMP-2 in bone tissue on weeks 1,2 and 4 in the experimental group was decreased in comparison with the control group(P<0.05).Conclusion SF can inhibit BH in TF rats.
作者
李玉斐
马智聪
LI Yufei;MA Zhicong(School of Anesthesiology,Shanxi Medical University,Shanxi,Taiyuan 030001,China;不详)
出处
《河北医药》
CAS
2023年第2期170-173,179,共5页
Hebei Medical Journal
基金
山西省自然科学基金面上项目(编号:201901D111368)。